SAS Output

19-NOV-2017 6:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 452 235
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 264 126
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 389 175
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 247 116
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 425 229
  A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 08-DEC-16 0 197
  A221405 Breast, ET interruption, Pregnancy Outcomes 15-OCT-15 0 58
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 408 180
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 227 81
  E2112 Brst,Adv,Exemestane+/-Entinostat 02-JAN-14 285 167
  NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA 24-DEC-14 0 4
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 447 229
 
CCD S1415CD TrACER CSF Standing Order Intervention for FN 01-SEP-16 20 35
  S1417CD Colorectal, Cost Cohort Study 13-MAY-16 199 60
  A011104 Preoperative Breast MRI 21-FEB-14 168 60
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 345 147
  A071102 GBM, adj TMZ +/- Veliparib 19-SEP-14 373 162
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 245 104
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 241 117
  EAY131 MATCH 12-AUG-15 466 244
 
GI S1505 Panc,Resect, Perioperative Chemo 12-OCT-15 310 124
  S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 01-SEP-16 319 149
  S1613 mCRC, Adv/Met, TP vs CETIRI 09-OCT-17 0 28
  A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT 01-DEC-16 0 50
  EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo 29-JAN-16 0 40
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 185 71
  N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX 13-JAN-12 0 161
  NRGGI002 Rectal, Ph II, Sensitization using TNT 12-OCT-16 320 132
  R0848 Panc, Adj, Erlotinib v ChemoRT 01-MAR-14 0 148
 
GU S1314 Blad, COXEN Neoadj. Chemo + Cyst 11-JUL-14 212 108
  S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 207 92
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 143 64
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 140 63
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 59 35
  EA8141 UTUC, HG, Chemo then Surg 27-JAN-15 154 75
  EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) 02-FEB-17 0 4
  NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel 30-DEC-16 0 103
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 162
 
LEUK S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP 01-APR-14 1 2
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 157 86
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 150 80
  NHLBIMDS LEUK, National MDS Study 05-APR-16 254 104
 
LUNG S1400 SCCA,Adv, Biomarker Master 15-JUN-14 437 218
  S1400F Non-Match: MEDI4736 + Tremelimumab 02-OCT-17 0 201
  S1400G HRRD: Talazoparib (BMN 673) 07-FEB-17 439 219
  S1400I Non-Match: Nivo + Ipi vs Nivo 18-DEC-15 434 217
  S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab 25-MAR-15 225 95
  S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 18-JUL-16 208 92
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 248
  A151216 ALCHEMIST0 - screening 06-FEB-14 452 251
  C30610 SCLC, Thoracic RT 21-MAR-08 239 118
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 456 257
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 406 230
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 320 143
  R1306 NSCLC,Adv,ALK/EGFR,TargetAgents 04-NOV-13 189 79
 
LYMPH S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob 10-AUG-17 0 58
  A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo 15-JUL-16 133 61
 
MELAN S1320 Adv, BRAF mut, Inter v Contin 22-JUL-14 229 102
  S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 15-OCT-15 390 170
  S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 73 31
  S1607 MELAN, Adv, T-VEC, MK-3475 02-OCT-17 0 6
  S1616 MELAN, Adv, Ipilimumab Nivolumab 17-JUL-17 0 54
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 350 144
  EA6141 Melan, Avd, Nivolumab+Ipi Sargmostim 01-MAR-16 312 126
 
MMYEL E1A11 MM, frontline, BLD vs CLD 22-NOV-13 314 137
 
OTHER A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo 02-SEP-14 51 29
  A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II 26-JAN-15 185 65
  A091305 HN, Adv, Thyroid PPAR agonist + Chemo 01-SEP-14 120 38
  A091401 Sarc, 18-JUN-15 233 91
  A091404 HN, AR+, Enzalutamide 25-SEP-15 93 39
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 0 64
  EAQ152 Communication & education in tumor profiling 26-SEP-16 241 104
  G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT 12-APR-10 0 6
  G0281 Ovar, Recur/prog LG, IC chemo vs trametinib 27-FEB-14 0 82
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 109
  NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo 04-FEB-16 344 163
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 317 141
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 191 69
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 247 98
  R0920 HN, Adv, Postop IMRT Cetuximab 24-DEC-13 327 151
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 274 121
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 329 114
  A211102 Breast, Atypia via RPFNA, Metformin v Placebo 01-FEB-15 25 10
  A211201 Breast Density, MA.32 companion 22-AUG-12 18 12
  EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis 02-SEP-16 0 10
 
SURV S1316 Compar. Effectiv. Trial for MBO 09-MAR-15 14 19
  S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 0 25
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 36
  EA9131 Leuk, Strategy to decrease early APL deaths 16-AUG-17 0 15
 
SXQOL A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 207 91
  A221102 Brst,AI Arthralgia,Testosterone 07-SEP-12 0 56